Microba Life Sciences Limited (AU:MAP) has released an update.
Microba Life Sciences Limited reported robust financial growth in its Q1 FY25 with cash receipts soaring by 184% and revenue by 239%, driven by strong sales of its MetaXplore tests in Australia. The company has also made strategic expansions into the UK market and transferred its non-core Research Services to focus on its core diagnostic microbiome testing business. With new leadership appointments, Microba is poised for further growth and market penetration.
For further insights into AU:MAP stock, check out TipRanks’ Stock Analysis page.